{"id":"NCT02509494","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","officialTitle":"A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-30","primaryCompletion":"2019-06-28","completion":"2019-07-03","firstPosted":"2015-07-28","resultsPosted":"2022-07-18","lastUpdate":"2022-07-18"},"enrollment":1023,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Ebola Virus Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.ZEBOV","otherNames":[]},{"type":"BIOLOGICAL","name":"MVA-BN-Filo","otherNames":[]},{"type":"BIOLOGICAL","name":"MenACWY","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Stage 1: Active vaccination","type":"EXPERIMENTAL"},{"label":"Stage 2: Active vaccination","type":"EXPERIMENTAL"},{"label":"Stage 2: Active vaccination for children","type":"EXPERIMENTAL"},{"label":"Stage 2: Control vaccination","type":"ACTIVE_COMPARATOR"},{"label":"Stage 2: Control vaccination for children","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is the evaluation of the safety and immunogenicity of two candidate Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo, in a 2-dose heterologous regimen.","primaryOutcome":{"measure":"Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8)","timeFrame":"7 days post dose 1 (Day 8)","effectByArm":[{"arm":"Stage 1 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo (Ad26.ZEBOV)","deltaMin":12,"sd":null},{"arm":"Stage 2 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo","deltaMin":51,"sd":null},{"arm":"Stage 2 (>=18 Years): MenACWY, Placebo","deltaMin":17,"sd":null},{"arm":"Stage 2 (12-17 Years): Ad26.ZEBOV, MVA-BN-Filo","deltaMin":14,"sd":null},{"arm":"Stage 2 (12-17 Years): MenACWY, Placebo","deltaMin":3,"sd":null},{"arm":"Stage 2 (4-11 Years): Ad26.ZEBOV, MVA-BN-Filo","deltaMin":30,"sd":null},{"arm":"Stage 2 (4-11 Years): MenACWY, Placebo","deltaMin":2,"sd":null},{"arm":"Stage 2 (1-3 Years): Ad26.ZEBOV, MVA-BN-Filo","deltaMin":21,"sd":null},{"arm":"Stage 2 (1-3 Years): MenACWY, Placebo","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Sierra Leone"]},"refs":{"pmids":["38603720","37631885","34529963","34529962","29895178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":43},"commonTop":["Malaria","Headache","Upper Respiratory Tract Infection","Respiratory Tract Infection","Nasopharyngitis"]}}